The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey

References

• Online mendelian inheritance in man. #135100 fibrodysplasia ossificans progressiva; FOP. Updated 2017. [cited 2022 Jun 1]. Available from: https://www.omim.org/entry/135100
   Google Scholar
• Kaplan FS, Tabas JA, Gannon FH, et al. The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Joint Surg Am. 1993;75(2):220–230.
   PubMedGoogle Scholar
• Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379–390.
   PubMedGoogle Scholar
• Liljesthröm M, Pignolo R, Kaplan F. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020;5(2):31–36.
   Google Scholar
• Baujat G, Choquet R, Bouée S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.
   PubMedGoogle Scholar
• Pignolo RJ, Hsiao EC, Baujat G, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350.
   PubMed Web of Science ®Google Scholar
• Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525–527.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang K, Song L, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386–391.
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;2(2):437–448.
   Google Scholar
• Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650–656.
   PubMed Web of Science ®Google Scholar
• Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64(1):76–83.
   PubMedGoogle Scholar
• Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686–691.
   PubMedGoogle Scholar
• Kaplan FS, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Int Clin Counc FOP. 2021;2:1–127.
   Google Scholar
• Pignolo RJ, Cheung K, Kile S, et al. Self-reported baseline phenotypes from the international Fibrodysplasia Ossificans Progressiva (FOP) association global registry. Bone. 2020;134:115274.
   PubMed Web of Science ®Google Scholar
• Levy CE, Lash AT, Janoff HB, et al. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol. 1999;8(1):29–33.
   PubMedGoogle Scholar
• Peng K, Cheung K, Lee A, et al. Longitudinal evaluation of pain, flare-up, and emotional health in fibrodysplasia ossificans progressiva: analyses of the International FOP Registry. JBMR Plus. 2019;3(8):e10181.
   PubMedGoogle Scholar
• IFOPA. FOP Registry [cited 2022 Jun 1]. Available from: https://fopregistry.org/
   Google Scholar
• Pignolo RJ, Baujat G, Brown MA, et al. Greater heterotopic ossification burden is associated with reduced mobility, function, and quality of life in individuals with FOP. J Bone Miner Res. 2021;37(Suppl 1):71.
   Google Scholar
• Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Rockville (MD): Office of the Surgeon General (US); 2004.
   Google Scholar
• Kodra Y, Cavazza M, de Santis M, et al. Social economic costs, health-related quality of life and disability in patients with cri du chat syndrome. Int J Environ Res Public Health. 2020;17(16):5951.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529–536.
   PubMed Web of Science ®Google Scholar
• Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.
   PubMedGoogle Scholar
• Ernstsson O, Janssen MF, Heintz E. Collection and use of EQ-5D for follow-up, decision-making, and quality improvement in health care - the case of the Swedish national quality registries. J Patient Rep Outcomes. 2020;4(1):78.
   PubMedGoogle Scholar
• Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ. 2017;358:j3453.
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017;101:123–128.
   PubMed Web of Science ®Google Scholar
• Kaplan FS, Al Mukaddam M, Pignolo RJ. Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP). Bone. 2018;109:158–161.
   PubMed Web of Science ®Google Scholar
• Pignolo RJ, Kimel M, Whalen J, et al. Validity and reliability of the fibrodysplasia ossificans progressiva physical function questionnaire (FOP-PFQ), a patient-reported, disease-specific measure. J Bone Miner Res. 2020;35:312.
   Web of Science ®Google Scholar
• EQ-5D Instruments. [cited 2022 Jun 1]. Available from: www.euroqol.org/eq-5d-instruments
   Google Scholar
• Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727.
   PubMed Web of Science ®Google Scholar
• Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–880.
   PubMed Web of Science ®Google Scholar
• Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–941.
   PubMed Web of Science ®Google Scholar
• Hébert R, Bravo G, Préville M. Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging. 2000;19(4):494–507.
   Web of Science ®Google Scholar
• Zarit S, Zarit J. Instructions for the burden interview. University Park: Pennsylvania State University; 1987.
   Google Scholar
• Pignolo RJ, Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):98.
   PubMedGoogle Scholar
• Kaplan FS, Strear CM, Zasloff MA. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1994;304:238–247.
   Google Scholar
• Al Mukaddam M, Pignolo RJ, Baujat G, et al. A natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcomes. J Endocr Soc. 2020;4(Suppl 1):OR29–05.
   Google Scholar
• Nakahara Y, Kitoh H, Nakashima Y, et al. Longitudinal study of the activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva. Disabil Rehabil. 2019;41(6):699–704.
   PubMed Web of Science ®Google Scholar
• Zhou T, Guan H, Wang L, et al. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review. Front Public Health. 2021;9:675523.
   PubMed Web of Science ®Google Scholar
• Poder TG, Wang L, Carrier N. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec. BMJ Open. 2020;10(9):e035722.
   PubMed Web of Science ®Google Scholar
• Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–816.
   PubMed Web of Science ®Google Scholar
• EURODIS. Juggling care and daily life. The balancing act of the rare disease community. A Rare Barometer survey. 2017. [cited 2022 Aug 10]. Available from: https://innovcare.eu/survey-juggling-care-daily-life-balancing-act-rare-disease-community/
   Google Scholar
• National Center for Health Statistics (NCHS). Percentage of having a doctor visit for any reason in the past 12 months for adults aged 18 and over, United States, 2019–2020. National Health Interview Survey [cited 2022 Feb 5]. Available from: https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html
   Google Scholar
• National Center for Health Statistics (NCHS). Percentage of having a dental exam or cleaning in the past 12 months for adults aged 18 and over, United States, 2019–2020. National Health Interview Survey [cited 2022 Feb 5]. Available from: https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html
   Google Scholar
• International Fibrodysplasia Ossificans Progressiva Association (IFOPA). 2020 FOP registry annual report. 2021. [cited 2022 Jun 1].Available from: https://www.ifopa.org/2020_fop_registry_annual_report
   Google Scholar
• The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part I: cost of illness. Can J Neurol Sci. 1998;25(1):23–30.
   PubMed Web of Science ®Google Scholar
• International Labour Organization. ILO monitor: COVID-19 and the world of work. Seventh edition. 2021. [cited 2022 Jun 1]. Available from: https://www.ilo.org/global/topics/coronavirus/impacts-and-responses/WCMS_767028/lang--en/index.htm
   Google Scholar
• U.S. Bureau of Labor Statistics. Supplemental data measuring the effects of the coronavirus (COVID-19) pandemic on the labor market 2020. Updated 2022. [cited 2022 Jun 1]. Available from: https://www.bls.gov/cps/effects-of-the-coronavirus-covid-19-pandemic.htm
   Google Scholar
• Yang G, Cintina I, Pariser A, et al. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022 ;17(1):163.
   PubMed Web of Science ®Google Scholar
• Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675–697.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England. Updated 2019. [cited 2022 Aug 15]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l
   Google Scholar